X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 52
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.950 |
| 2 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.927 |
| 3 | SRR8942969 | — | — | 0.923 |
| 4 | SRR33346956 | — | — | 0.911 |
| 5 | SRR12202445 | — | — | 0.901 |
| 6 | TCGA-MP-A4T4-01A-11R-A262-07 | — | cohortA1 | 0.897 |
| 7 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.894 |
| 8 | MBCProject_0375_T1_B_RNA | — | D | 0.893 |
| 9 | SRR12202486 | — | — | 0.891 |
| 10 | C3N-03233 | — | cohortA1 | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |